Understanding and Applying Regulatory Guidance on the Nonclinical Development of Biotechnology-Derived Pharmaceuticals
Authors:
- 1 January 2006
- journal article
- Published by Springer Nature in BioDrugs
- Vol. 20 (1) , 25-52
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- PDE4 inhibition: a novel approach for the treatment of inflammatory bowel diseaseTrends in Pharmacological Sciences, 2004
- Tissue Engineering: Progress and ChallengesPlastic and Reconstructive Surgery, 2004
- Tissue engineering: viable technologies seeking regulation – a Finnish perspectiveDrug Discovery Today, 2004
- Preclinical safety testing of biotechnology-derived pharmaceuticalsMolecular Biotechnology, 2004
- Legal and Scientific Considerations in Nonclinical Assessment of Biotechnology ProductsDrug Information Journal, 2003
- Human tissue engineered products—drugs or devices?BMJ, 2003
- The European Agency for the Evaluation of Medicinal Products’ Centralized Procedure for Product Approval: Current StatusDrug Information Journal, 1999
- Safety Assessment of Biotechnology-Derived Pharmaceuticals: ICH and BeyondToxicologic Pathology, 1999
- Modern Biotechnology: a Review of Current Regulatory Status and Identification of Research and Regulatory NeedsToxicology and Industrial Health, 1988
- An overview of safety and regulatory aspects of the new biotechnologyRegulatory Toxicology and Pharmacology, 1983